Conference Article

LDN and Psoriasis by Dr Pamela Smith

Two recent reports suggested that low-dose naltrexone is a beneficial and convenient therapy for psoriasis. Patients included 13 females, 2 males; mean age 57 years; mean psoriasis duration 16 years. Of the patients, 8 had psoriatic arthritis. In the past, 5 had completely failed and 10 had partially responded to =1 topical therapies. Patients used a self-assessed Likert scale and the response to 4.5 mg of oral naltrexone was as follows: 8/15 marked improvement; 2/15 somewhat improved; and 5/15 unchanged. Three adverse events included insomnia, diarrhea, and self-limited headache. In conclusion, marked improvement was seen by 53% of the 15 patients. 

 Int J Pharm Compd. Mar-Apr 2020;24(2):94-96.